TD Asset Management Inc Buys New Shares in Abivax SA Sponsored ADR $ABVX

TD Asset Management Inc purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,486 shares of the company’s stock, valued at approximately $3,947,000. TD Asset Management Inc owned approximately 0.06% of Abivax as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of ABVX. Octagon Capital Advisors LP lifted its holdings in shares of Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after purchasing an additional 37,000 shares during the last quarter. Millennium Management LLC raised its holdings in Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after buying an additional 56,235 shares during the period. Boothbay Fund Management LLC raised its holdings in Abivax by 52.5% during the 2nd quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock worth $6,659,000 after buying an additional 299,770 shares during the period. Aberdeen Group plc lifted its stake in Abivax by 10.8% during the third quarter. Aberdeen Group plc now owns 787,417 shares of the company’s stock valued at $66,852,000 after buying an additional 76,901 shares in the last quarter. Finally, Saturn V Capital Management LP boosted its holdings in shares of Abivax by 12.6% in the second quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock worth $4,762,000 after buying an additional 69,553 shares during the period. 47.91% of the stock is owned by institutional investors.

Abivax Stock Performance

Shares of ABVX stock opened at $111.10 on Wednesday. The firm has a market cap of $8.78 billion, a P/E ratio of -26.58 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. Abivax SA Sponsored ADR has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The stock’s 50-day moving average is $123.24 and its two-hundred day moving average is $106.92.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ABVX has been the subject of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $142.00 price target on shares of Abivax in a research report on Tuesday, December 16th. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Wedbush started coverage on Abivax in a research report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target on the stock. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Morgan Stanley increased their price target on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Abivax has a consensus rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.